Asif Mohamed, MD
Endocrinology, Diabetes & Metabolism · Baltimore, MDNPI 1962484261
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,150 of the $30,610 with a category attached, or 62.6%. 40 manufacturers reported payments, led by AbbVie at 39.8% of the total. Reporting peaked in 2021 at $10,801 and has fallen 88.2% since, to $1,272 in 2025. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $59.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- AstraZeneca$10K
- Sanofi-aventis U.S. LLC$3K
- Lilly USA, LLC$1K
- Amneal Pharmaceuticals LLC$614
- Corcept Therapeutics$542
- plus $3K from 34 others
What the payments were for
- Consulting fees$2,4658%
- Speaking & faculty fees$19,15063%
- Travel & lodging$1480%
- Food & beverage$8,73529%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 75 | $12,196 |
| AstraZeneca | 110 | $9,724 |
| Sanofi-aventis U.S. LLC | 35 | $2,780 |
| Lilly USA, LLC | 78 | $1,376 |
| Amneal Pharmaceuticals LLC | 44 | $614 |
| Corcept Therapeutics | 21 | $542 |
| Abbott | 7 | $494 |
| Novo Nordisk | 22 | $414 |
| Mannkind Corporation | 21 | $386 |
| Amgen | 19 | $379 |
| Xeris Pharmaceuticals, Inc. | 11 | $224 |
| Radius Health, Inc. | 7 | $150 |
| Tandem Diabetes Care, Inc. | 7 | $143 |
| Medtronic | 6 | $140 |
| Dexcom, Inc. | 6 | $122 |
| Boehringer Ingelheim | 6 | $106 |
| Shire North American Group Inc | 5 | $97 |
| Insulet Corporation | 5 | $87 |
| Cequr Corporation | 3 | $80 |
| Recordati_rare_diseases_inc. | 3 | $66 |
| Tolmar, Inc. | 3 | $59 |
| Halozyme Inc | 2 | $53 |
| Antares Pharma, Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $36 |
| Valeritas, Inc. | 1 | $32 |
| Almatica Pharma LLC | 1 | $24 |
| Nevro Corp. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Bayer | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $19 |
| BD | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $17 |
| Madrigal Pharmaceuticals | 1 | $16 |
| Pfizer | 1 | $15 |
| Merck | 1 | $15 |
| Lifescan, Inc. | 1 | $14 |
| Companion Medical, Inc. | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Synthroid$11,501
- FARXIGA$7,976
- DISEASE STATE$2,215
- FreeStyle Libre Pro$375
How this compares
$30,610 in reported general payments places this provider in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 164 | $260,553 |
| MounjaroTirzepatide | 135 | $165,704 |
| OzempicSemaglutide | 92 | $107,906 |
| JardianceEmpagliflozin | 95 | $105,569 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $63,629 |
| FarxigaDapagliflozin Propanediol | 58 | $56,550 |
| Xigduo XrDapaglifloz Propaned/Metformin | 35 | $48,540 |
| JanuviaSitagliptin Phosphate | 36 | $38,290 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $36,210 |
| Gvoke Hypopen 2-PackGlucagon | 13 | $25,777 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $18,372 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $16,041 |
| GlyxambiEmpagliflozin/Linagliptin | 17 | $14,735 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $14,570 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $13,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,376 | $431,169315 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $106 | $136,346132 claims |
| Novo NordiskOzempic | $414 | $107,90692 claims |
| AstraZenecaFarxiga | $9,724 | $56,55058 claims |
| MerckJanuvia | $15 | $38,29036 claims |
| AbbVieSynthroid | $12,196 | $8,78384 claims |
| IBSA Pharma Inc.Tirosint | $22 | $4,51224 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $614 | $3,038175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Baltimore
- Philip LevinBaltimore$489K
- Adrian DobsBaltimore$149K
- Todd BrownBaltimore$143K
- Roberto SalvatoriBaltimore$53K
- Nowreen HaqBaltimore$40K
- Sherita GoldenBaltimore$27K
- Jean ParkBaltimore$13K
- Mansur ShomaliBaltimore$11K
- Malek CheikhBaltimore$9K
- Paul SackBaltimore$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.